-
Mashup Score: 9Incorporating Genetic Testing Into the Care of Patients with ALS/FTD - 5 month(s) ago
Dr. Gordon Smith talks with Laynie Dratch about integrating genetic testing into patient care for persons with Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) spectrum disorders. Read the related article in . Disclosures can be found at Neurology.org
Source: directory.libsyn.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 37Stathmin-2 loss leads to neurofilament-dependent axonal collapse driving motor and sensory denervation - Nature Neuroscience - 5 month(s) ago
Stathmin-2 is lost in amyotrophic lateral sclerosis. Here the authors show that stathmin-2 has an essential role in the maintenance of axon structure, with its loss from adult motor neurons resulting in axonal collapse and muscle denervation.
Source: www.nature.comCategories: General Medicine News, NeurologyTweet-
Stathmin-2 loss, which occurs as a result of TDP-43 dysfunction in #ALS, leads to neurofilament-dependent axonal collapse, driving motor and sensory denervation https://t.co/lGsCAo5sn0
-
-
Mashup Score: 5Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort - 6 month(s) ago
Background Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurogenerative disease caused by combined genetic susceptibilities and environmental exposures. Identifying and validating these exposures are of paramount importance to modify disease risk. We previously reported that persistent organic pollutants (POPs) associate with ALS risk and survival and aimed to replicate these findings in a new cohort. Method Participants with and without ALS recruited in Michigan provided plasma samples for POPs analysis by isotope dilution with triple quadrupole mass spectrometry. ORs for risk models and hazard ratios for survival models were calculated for individual POPs. POP mixtures were represented by environmental risk scores (ERS), a summation of total exposures, to evaluate the association with risk (ERSrisk) and survival (ERSsurvival). Results Samples from 164 ALS and 105 control participants were analysed. Several individual POPs significantly associated with ALS, including 8
Source: jnnp.bmj.comCategories: General Medicine News, General NewsTweet-
Drawing a tube of blood could assess #ALS risk from environmental toxin exposure @umich https://t.co/Eu6ZDnFSuo https://t.co/nCDSNVkdT9
-
-
Mashup Score: 0Incorporating Genetic Testing Into the Care of Patients With Amyotrophic Lateral Sclerosis/Frontotemporal Degeneration Spectrum Disorders - 7 month(s) ago
Purpose of Review Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) spectrum disorders have a strong genetic component. Genetic counselors are a limited resource, and therefore, other providers must be prepared to integrate genetic testing into their practice. Recent Findings Recent ALS/FTD studies have demonstrated that lack of family history does not preclude a genetic etiology. The benefits of a genetic diagnosis have expanded to include the potential to treat; thus, genetic testing is increasingly recommended to be offered to all persons with ALS/FTD. Summary Offering genetic testing to persons with ALS/FTD spectrum disorders should be part of routine clinical neurologic care. All genetic testing should include discussion about the medical and psychosocial implications of testing for the patient and family members. Neurologists should be prepared to facilitate this process and recognize when referral to a genetic counselor is indicated.
Source: cp.neurology.orgCategories: Latest Headlines, NeurologyTweet-
Chambers and colleagues posit that offering genetic testing to persons with ALS/FTD spectrum disorders should be part of routine clinical neurologic care. Read this Innovations in Neurologic Practice article: https://t.co/nJMkLsZc25 #NeuroTwitter #ALS https://t.co/2NDoojCwmU
-
-
Mashup Score: 3European regulators consider appeal over Amylyx ALS drug - 7 month(s) ago
This week, European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s ALS treatment.
Source: www.statnews.comCategories: General Medicine News, Latest HeadlinesTweet-
European regulators are considering an appeal from Amylyx Pharmaceuticals after initially recommending against approving the company’s #ALS treatment. https://t.co/VWCa2QQIir
-
-
Mashup Score: 0
Nuro announced that a teenager with amyotrophic lateral sclerosis (ALS) regained some communication ability with its technology.
Source: www.massdevice.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@nuro_corp achieves communication in locked-in patient with its neurotechnology - teenager completely incapacitated by #ALS controlled critical communication, music & video content, using thought control, without any surgery, training or calibration https://t.co/9G1fy0LutZ
-
-
Mashup Score: 2
A panel of independent advisers to the FDA voted against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s supporting data did not meet the standard for approval.
Source: www.statnews.comCategories: General Medicine News, Latest HeadlinesTweet-
A panel of independent advisers to the FDA voted against a polarizing potential treatment for #ALS on Wednesday. https://t.co/jf0E3wsDx4
-
-
Mashup Score: 1FDA Panel Overwhelmingly Rejects ALS Cell Therapy - 7 month(s) ago
Echoing concerns from agency reviewers, advisors can’t find evidence of efficacy
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Nearly all members of an FDA advisory panel voted against the data presented for an investigational amyotrophic lateral sclerosis (#ALS) treatment on Wednesday. https://t.co/koKWEd7hza @MedPageNeuro @Judyreports
-
-
Mashup Score: 0Patient Story - 7 month(s) ago
In the fall of 2004, while at work Urbiha experienced some health symptoms affecting her left hand and arm that she initially thought might be part of the aging process.
Source: www.henryford.comCategories: General Medicine News, Latest HeadlinesTweet-
#ALS has a life expectancy of 2 to 5 years – but 17 years after her diagnosis, Laura has defied the odds. With her standing wheelchair, she even “danced” with her son at his wedding to the same song she danced with her husband to at their wedding: https://t.co/kaFNs3ahAE https://t.co/7UtSo05Dre
-
-
Mashup Score: 0
Agency scientists flagged numerous issues with Brainstorm’s stem cell treatment ahead of a high-profile Wednesday meeting of expert FDA advisers.
Source: www.healthcaredive.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
#FDA staff hold ‘major concerns’ with Brainstorm #ALS therapy, documents show - A panel of expert advisers will meet Wednesday to review the #stemcell treatment, which has become the latest test case in a debate over #regulatory flexibility. https://t.co/6LvpEiekSE
-
Neurology Podcast: Dr. Gordon Smith & Laynie Dratch discuss integrating genetic testing into patient care for persons with #ALS & frontotemporal degeneration spectrum disorders. Listen now: https://t.co/0Ha5eOhHs2 Article: https://t.co/lwMQNUu3dB @gordonsmithMD @LayniedratchC https://t.co/yqShCXTVfN